LogicBio Therapeutics, a preclinical gene editing biotech developing therapies for rare diseases, announced terms for its IPO on Tuesday.
The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14. Insiders intend to purchase up to $30 million of the IPO (40% of the deal). At the midpoint of the proposed range, LogicBio Therapeutics would command a fully diluted market value of $294 million.
LogicBio Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol LOGC. Jefferies, Barclays and William Blair are the joint bookrunners on the deal. It is expected to price during the week of October 15, 2018.
